Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems

Exclusion Criteria

• •1. Predominant mucinous component on initial MRI, biopsy and / or definitive pathology. Mucin may lead to overestimation of ADC values on DWIs.
• •2. Contraindications to the MRI procedure (non compatible pacemaker or other metallic foreign body, severe claustrophobia).
• •3. Exclusive radiation therapy.
• •4. Other associated neo-adjuvant treatment.
• •5. Delayed completion of the surgery (more than approximately 10 weeks after the end of the nRCT) or cancellation of the surgical procedure.
• •6. Contraindications to capecitabine: Severe hepatic impairment, severe renal impairment (creatinine clearance \<30 ml / min),
• •7. Known deficiency of Dihydropyrimidine dehydrogenase (DPD), known hypersensitivity to 5-FU / capecitabine and / or its excipients.
• •8. Participation in a protocol with concurrent treatment.
• •9. Pregnant or likely to be pregnant (without effective contraception) or breastfeeding
• •10. Person in emergency situation, person of legal age subject to a legal protection measure, or unable to express his / her consent.
• •11. Impossibility of attending the medical examination of the test for geographical, social or psychological reasons.